Cyclacel Cancer Study Showing Weak Data
August 29th, 2008
Cyclacel Pharmaceuticals Inc. said an independent data review committee recommended that the company’s Phase IIb seliciclib study in non-small lung cancer should continue, even though the data probably won’t show an improvement in progression-free survival – the study’s main objective.